Orgovyx (Relugolix) Patient Counseling
Counsel patients starting Orgovyx to take a 360 mg loading dose on day 1, followed by 120 mg once daily at the same time each day, with tablets swallowed whole and not crushed or chewed. 1
Dosing Instructions
- Loading dose: 360 mg on the first day of treatment
- Maintenance dose: 120 mg once daily at approximately the same time each day
- Can be taken with or without food
- Swallow tablets whole—do not crush or chew 1
Missed Dose Protocol
- If remembered within 12 hours: Take the missed dose immediately
- If more than 12 hours have passed: Skip the missed dose and resume with the next scheduled dose
- If treatment is interrupted for more than 7 days: Restart with a 360 mg loading dose on day 1, then continue with 120 mg daily 1
Expected Treatment Effects
Rapid testosterone suppression occurs within approximately 4 days (median 1.13 months to castrate levels <50 ng/dL), significantly faster than traditional injectable GnRH agonists like leuprolide (29 days) 2, 3, 4. This rapid suppression occurs without an initial testosterone surge ("flare-up"), which is a critical advantage over GnRH agonists that can temporarily worsen symptoms 5, 4.
Cardiovascular Safety Advantage
Orgovyx demonstrates a 54% reduction in major cardiovascular events compared to leuprolide (HR 0.46,95% CI 0.24-0.88) 2, 5. This is particularly important for patients with pre-existing cardiac risk factors, making Orgovyx a preferred option in this population 4, 6.
Common Side Effects
Counsel patients that side effects are consistent with testosterone suppression and include:
- Hot flashes
- Fatigue
- Musculoskeletal effects
- Most adverse events are grade 1-2 in severity 4
Critical Safety Warnings
QT Interval Prolongation
Androgen deprivation therapy may prolong the QT/QTc interval. Inform patients with:
- Congenital long QT syndrome
- Congestive heart failure
- Frequent electrolyte abnormalities
- Those taking QT-prolonging medications
These patients require periodic ECG and electrolyte monitoring 1.
Hypersensitivity Reactions
Advise patients to immediately discontinue Orgovyx and seek medical care if they experience:
- Pharyngeal edema
- Angioedema symptoms
- Any severe allergic reactions
Orgovyx is contraindicated in patients with severe hypersensitivity to relugolix 1.
Drug Interactions
P-glycoprotein (P-gp) Inhibitors
Avoid co-administration with oral P-gp inhibitors. If unavoidable:
- Take Orgovyx first
- Separate dosing by at least 6 hours
- Treatment may be interrupted for up to 2 weeks if a short course of P-gp inhibitor is required 1
Combined P-gp and Strong CYP3A Inducers
Avoid co-administration. If unavoidable:
- Increase Orgovyx dose to 240 mg once daily during co-administration
- Resume 120 mg daily after discontinuation of the inducer 1
Treatment Reversibility
A unique advantage of Orgovyx is rapid testosterone recovery after discontinuation, with median time to recovery >50 ng/dL of 1.4 months (range 0.83-6.57 months) 3. This makes it particularly suitable for patients considering intermittent androgen deprivation therapy or those who may need treatment interruption.
Compliance and Cost Considerations
Medication adherence is critical—real-world data shows 94% of days covered among compliant patients 6. However, cost is the primary barrier to initiation (50% of non-fills) 6. Discuss:
- Financial assistance programs
- Insurance coverage verification before prescribing
- Specialty pharmacy coordination
Among patients who switched from injectable ADT to Orgovyx, 79% reported feeling similar or better on therapy 6.
Continuation of Therapy
Treatment is typically continued even upon development of castration-resistant prostate cancer (nonmetastatic or metastatic CRPC) 1. Patients should understand this is generally a long-term commitment unless specific circumstances warrant discontinuation.